[对结直肠癌全球负担的比较分析]
1National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhonghua zhong liu za zhi [Chinese journal of oncology]
|April 23, 2025
概括
结肠直肠癌 (CRC) 的发病率和死亡率在中国很高,尽管最近有所减少. 中国的生存率落后于美国和英国,突出了针对可修改的风险因素的有针对性的预防策略的需要.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 结肠直肠癌 (CRC) 代表着一个重要的全球健康负担.
- 了解CRC发病率,死亡率和存活率的区域差异对于有效的公共卫生干预至关重要.
- 可修改的风险因素在CRC的发展和结果中发挥着重要作用.
研究的目的:
- 分析中国,美国和英国的CRC发病率,死亡率,生存模式以及可修改的风险因素分布.
- 为了在选定的国家中比较CRC生存率的时间趋势.
- 评估可修改的风险因素对中国CRC死亡的贡献.
主要方法:
- 使用GLOBOCAN数据库和现有文献进行二次数据分析.
- 计算CRC发病率和死亡率的年龄标准化率 (ASR).
- 五年净生存率的比较和可修改风险因素对CRC死亡的贡献的评估.
主要成果:
- 在2022年,全球CRC发病率为1.926亿例,死亡率为904,000例;中国占两者的27%.
- 中国的CRC死亡率 (8.6/100,000) 超过美国 (7.9/100,000),但低于英国 (11.8/100,000).
- 到2022年,中国的CRC死亡率显著降低,生存率有所改善,但仍然低于美国和英国. 可修改的风险因素对中国的CRC死亡作出了重大贡献,区域差异很大.
结论:
- 中国面临着相当大的CRC负担,与发达国家相比,持续存在生存差距.
- 针对性,区域特定的预防战略对于减轻CRC负担至关重要.
- 强调可修改的风险因素修改和优化临床管理对于改善中国CRC结果至关重要.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85
01:21Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
01:12Hazard Ratio
67
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
67
01:30Serum Laboratory Studies, Stool Test, Breath Test
234
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
234